CD247 and neoplasm: Also in 2017, a phase I clinical trial involving 23 metastatic colorectal cancer patients was launched to test the efficacy and safety of a CAR-T product targeting TAG-72 convolving a CD3ζ intracellular signaling domain, and the results showed effective CAR-T cell trafficking to the tumor site and reduced TAG-72 expression without clear evidence of off-tumor toxicity, despite symptoms of anti-CAR immune response in some patients (34).